Erschienen in:
01.04.2008 | Poster presentation
Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
verfasst von:
J Dhainaut, M Antonelli, P Wright, M Belger, M Cobas-Meyer, M Mignini, J Janes
Erschienen in:
Critical Care
|
Sonderheft 2/2008
Einloggen, um Zugang zu erhalten
Excerpt
In the European Union, drotrecogin alfa (activated) (DAA) is licensed (intravenous infusion, 96 hours) for adults with severe sepsis with multiple organ failure. In the PROWESS trial, DAA treatment was associated with significant mortality reduction and more rapid improvement in cardiovascular function over 7 days (decreased need for vasopressors). But 22% of DAA-treated patients remained on vasopressors at end infusion. The primary aim of this study was to investigate, in severe sepsis patients with persistent vasopressor dependency at the end of 96-hour commercial DAA treatment, whether continued administration of DAA for up to a further 72 hours results in more rapid resolution of vasopressor dependency compared with placebo (no DAA after commercial DAA infusion). Secondary objectives were mortality, biomarker changes, and safety. …